PRESS RELEASE published on 04/13/2026 at 07:00, 6 months 27 days ago Inside Information / Other news releases Innate Pharma releases total shares and voting rights as of April 9, 2026, in compliance with French regulations. Learn about its innovative immunotherapies for cancer patients Voting Rights Shares French Regulations Innate Pharma Immunothérapies
BRIEF published on 04/03/2026 at 07:05, 7 months 7 days ago Innate Pharma will participate in the Kempen Life Sciences Conference Biotechnology Conference Innate Pharma Immunothérapies Kempen Life Sciences
BRIEF published on 04/03/2026 at 07:05, 7 months 7 days ago Innate Pharma to Join Kempen Life Sciences Conference Biotechnology Investor Meetings Innate Pharma Cancer Immunotherapies Kempen Conference
BRIEF published on 04/03/2026 at 07:05, 7 months 7 days ago Innate Pharma participera à la Kempen Life Sciences Conference Conference Innate Pharma Biotechnologies Immunothérapies Kempen Life Sciences
BRIEF published on 04/03/2026 at 07:05, 7 months 7 days ago Innate Pharma participera à la conférence Kempen Life Sciences Biotechnologie Innate Pharma Réunions Avec Les Investisseurs Conférence De Kempen Immunothérapies Contre Le Cancer
PRESS RELEASE published on 04/03/2026 at 07:00, 7 months 7 days ago Inside Information / Other news releases Innate Pharma to participate in the Kempen Life Sciences Conference on April 15-16, 2026, in Amsterdam, Netherlands. The company is developing immunotherapies for cancer patients Biotechnology Innate Pharma Immunothérapies Cancer Patients Kempen Life Sciences Conference
PRESS RELEASE published on 04/03/2026 at 07:00, 7 months 7 days ago Informations privilégiées / Autres communiqués Innate Pharma participera à la conférence Kempen Life Sciences à Amsterdam, Pays-Bas, du 15 au 16 avril 2026, pour présenter ses traitements d'immunothérapies contre le cancer Conference Immunothérapie Cancer Innate Pharma Kempen Life Sciences
BRIEF published on 12/11/2025 at 07:05, 10 months 30 days ago Innate Pharma révèle son calendrier financier 2026 Biotechnologie Calendrier Financier Immunothérapie Innate Pharma Résultats 2026
BRIEF published on 12/11/2025 at 07:05, 10 months 30 days ago Innate Pharma annonce son calendrier financier pour 2026 Biotechnologie Calendrier Financier Informations Pour Les Investisseurs Innate Pharma Dates Clés De 2026
BRIEF published on 12/11/2025 at 07:05, 10 months 30 days ago Innate Pharma reveals its 2026 financial calendar Biotechnology Financial Calendar Immunotherapy Innate Pharma 2026 Results
Published on 11/10/2026 at 21:00, 39 minutes ago Golden Minerals Announces Completion of Offering for C$5,000,000
Published on 11/10/2026 at 14:45, 6 hours 54 minutes ago An Investigational Drug to Tackle Measles Outbreaks
Published on 11/10/2026 at 14:31, 7 hours 8 minutes ago First Breach Plans to Integrate Onboard AI Computing into CQS and LRS Drone Platforms
Published on 11/10/2026 at 14:30, 7 hours 9 minutes ago Stabilis Solutions Announces Three-Year Take-Or-Pay LNG Supply Agreement with Existing Aerospace Customer
Published on 11/10/2026 at 14:30, 7 hours 9 minutes ago ACCESS Newswire Reports Third Quarter 2026 Results
Published on 11/10/2026 at 19:21, 2 hours 18 minutes ago ALTHEORA, Mäder Composites France et IPC s'associent pour donner une seconde vie aux matériaux composites
Published on 11/10/2026 at 18:54, 2 hours 45 minutes ago REPLOID Group AG pursues entry in the US market and secures exclusivity to conduct due diligence for the potential acquisition of Chapul, LLC.
Published on 11/10/2026 at 18:45, 2 hours 54 minutes ago Special Optics Introduces Purpose-Built Microscope Objectives for Quantum Applications
Published on 11/10/2026 at 18:00, 3 hours 39 minutes ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 3 hours 54 minutes ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 4 hours 4 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 4 hours 8 minutes ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
